# Safety and Efficacy of PEG-Encapsulated Islet Allografts Implanted in Type I Diabetic Recipients

> **NCT00260234** · PHASE1,PHASE2 · TERMINATED · sponsor: **Novocell** · enrollment: 12 (—)

## Conditions studied

- Diabetes Mellitus, Type 1

## Interventions

- **BIOLOGICAL:** Allogeneic Cultured Islet Cells (human); Encapsulated

## Key facts

- **NCT ID:** NCT00260234
- **Lead sponsor:** Novocell
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-11
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 12 (—)
- **Why stopped:** Stopped in December 2007
- **Last updated:** 2014-09-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00260234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00260234, "Safety and Efficacy of PEG-Encapsulated Islet Allografts Implanted in Type I Diabetic Recipients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00260234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*